Kamada (KMDA) Downgraded by ValuEngine

ValuEngine downgraded shares of Kamada (NASDAQ:KMDA) from a hold rating to a sell rating in a research note issued to investors on Wednesday morning.

KMDA has been the subject of a number of other reports. BidaskClub raised shares of Kamada from a hold rating to a buy rating in a research note on Thursday, September 27th. Zacks Investment Research lowered shares of Kamada from a hold rating to a sell rating in a research note on Thursday, November 15th. Two research analysts have rated the stock with a sell rating and three have assigned a buy rating to the stock. The company presently has an average rating of Hold and a consensus target price of $8.08.

Shares of KMDA opened at $4.68 on Wednesday. The firm has a market cap of $188.53 million, a PE ratio of 17.34 and a beta of 1.32. Kamada has a 12-month low of $4.35 and a 12-month high of $6.45. The company has a quick ratio of 3.31, a current ratio of 4.86 and a debt-to-equity ratio of 0.01.



Kamada (NASDAQ:KMDA) last issued its earnings results on Monday, November 12th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.01) by ($0.05). The company had revenue of $14.98 million for the quarter, compared to analysts’ expectations of $25.99 million. Kamada had a net margin of 10.60% and a return on equity of 11.70%. Analysts predict that Kamada will post 0.27 EPS for the current year.

Several hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc raised its holdings in shares of Kamada by 11.6% in the third quarter. Vanguard Group Inc now owns 583,797 shares of the biotechnology company’s stock valued at $3,620,000 after acquiring an additional 60,866 shares in the last quarter. Vanguard Group Inc. raised its holdings in shares of Kamada by 11.6% in the third quarter. Vanguard Group Inc. now owns 583,797 shares of the biotechnology company’s stock valued at $3,620,000 after acquiring an additional 60,866 shares in the last quarter. Worth Venture Partners LLC raised its holdings in shares of Kamada by 203.4% in the third quarter. Worth Venture Partners LLC now owns 155,719 shares of the biotechnology company’s stock valued at $963,000 after acquiring an additional 104,397 shares in the last quarter. Renaissance Technologies LLC raised its holdings in shares of Kamada by 17.9% in the third quarter. Renaissance Technologies LLC now owns 548,100 shares of the biotechnology company’s stock valued at $3,398,000 after acquiring an additional 83,200 shares in the last quarter. Finally, Altshuler Shaham Ltd bought a new stake in shares of Kamada in the third quarter valued at about $2,512,000. Hedge funds and other institutional investors own 12.51% of the company’s stock.

About Kamada

Kamada Ltd. develops, produces, and markets specialty plasma-derived protein therapeutics. It operates through two segments, Proprietary Products and Distribution. The company offers respiratory products, including Glassia for use in augmentation and maintenance therapy in adults with emphysema due to congenital Alpha-1 Antitrypsin deficiency (AATD).

Featured Story: Why is insider trading harmful?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Kamada Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply